BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Stock Up 15.9 %

Shares of BioLineRx stock opened at $0.54 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. BioLineRx has a 52-week low of $0.39 and a 52-week high of $1.89. The company has a market capitalization of $42.88 million, a P/E ratio of -1.19 and a beta of 1.48. The company has a 50 day moving average of $0.51 and a 200 day moving average of $0.62.

Institutional Investors Weigh In On BioLineRx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. PVG Asset Management Corp acquired a new position in BioLineRx in the second quarter valued at $70,000. Atria Investments Inc boosted its holdings in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the period. Finally, CVI Holdings LLC purchased a new stake in BioLineRx in the 2nd quarter valued at $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.